Skip to main content
OpenTrials
Completed

NCT Number: NCT06955923

Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty

This study will evaluate the ability of trigger point injections completed immediately following a total knee arthroplasty decrease pain scores and opioid use compared to sham injections. Given the current state of opioid dependency in the United States there needs to be a more focused attempt at treating post-operative pain without use of opioids. Given the manipulation of soft tissue during a total knee arthroplasty there seems to be a high correlation with pain and myofascial pain syndrome. This study will include an experimental (trigger point injection) and control (sham injection) group who are all undergoing a total knee arthroplasty. This is a pilot study that will include a maximum of 100 total patients (although it is planned for the study to be much smaller with a planned 10-15 patients per group). The procedure that will be completed is a trigger point injection with use of 1% lidocaine without epinephrine along the distal aspect of the vastus medialis and lateralis, proximal aspect of the medial and lateral gastrocnemius muscle bellies. The sham injection will be completed by pressing the needle against the skin without injecting any fluid. There will be a "blind" between the patient and the needle with both arms of the study. These patients will be followed up on POD1, and during weeks 2 and 6 follow-up where they will be given questionnaires to assess pain (visual analogue scale) and opioid use, and asked to bring their opioid medications to the clinic to assess the morphine milligrams equivalent (MME).

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

David Grant Medical Center

Fairfield, California, 94535, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 45 years or older
  • Planned to undergo primary total knee arthroplasty
  • Able to speak, read, and understand English
  • Willing to complete a study questionnaires
  • Willing to bring in their medications to be counted
  • DoD beneficiaries
  • No allergy to lidocaine
  • Not fearful of needles.

Exclusion criteria

  • Chronic opioid users (daily use of prescribed opioids for at least 90 days)
  • Diagnosed with Fibromyalgia
  • Non-English speaking
  • Unable to read English
  • Unable to understand English
  • Pregnant
  • Allergy to lidocaine
  • Not willing to complete study questionnaires
  • Not willing to bring in their medications to be counted
  • Not a DoD beneficiary
  • Fearful of needles

Treatment and study plan

Trigger point injection (lidocaine)

Drug

A trigger point injection utilizing lidocaine 1% without epinephrine will be injected into several muscles bellies immediately following surgery to halt a trigger point from forming. One group will receive this type of intervention and the sham group will not receive any type of injection.

Sham Comparator

Other

This arm of the study will not receive any injection.

Primary outcomes

  1. Pain Scores on the Visual Analog Scale

    Time frame: From enrollment to the end of treatment at 6 weeks

    • Change in Visual Analog Scale (VAS) pain scores

    The VAS is a numbered scale assessing pain severity using a number which describes the average level of pain since being discharged. Participants are to put a hash mark "/" on a numbered scale ranging from 0-100. Zero (0) is no pain and 100 is severe intolerable pain

Secondary outcomes

  1. Opioid Use

    Time frame: From enrollment to the end of treatment at 6 weeks

    • Compare the total opioid use between study groups (experimental, sham comparator).

    Opioid use will be measured during their inpatient stay using the Medication Administration Record (MAR) Summary in the electronic medical record; and completing an Opioid Use questionnaire and counting the number of pills remaining during post-operative/follow-up study visits. Inpatient opioid use will be calculated by using the morphine dosage and number of doses per day. Outpatient opioid use will be obtained by reviewing responses to the Opioid Use questionnaire and counting the number of pills remaining from the prescription given at the time of discharge. Participants will be asked to bring their medication (opioids) to their post-operative/follow-up study visits. This method will allow the investigator to measure total opioid use (injectable and pill) during their inpatient and outpatient course.

Sponsors and collaborators

Lead sponsor

David Grant U.S. Air Force Medical Center

Fed

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 2, 2025
Registry last updated
Feb 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.